Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the biotech journey of Cormedix means navigating dense clinical data, FDA risk factors, and liquidity notes buried deep in SEC paperwork. If you have ever typed “Cormedix SEC filings explained simply” or hunted for a “Cormedix annual report 10-K simplified,” you know how time-consuming that process can be. Our platform starts by decoding the science behind DefenCath and then surfaces the precise passages that discuss hemodialysis infection rates, regulatory milestones, and supply-chain contingencies—without the 200-page slog.
Stock Titan’s AI-powered summaries highlight exactly where the 10-K details cash burn, where the latest “Cormedix quarterly earnings report 10-Q filing” updates clinical spend, and when a “Cormedix 8-K material events explained” alert signals new FDA correspondence. Need real-time oversight of “Cormedix insider trading Form 4 transactions” or an instant ping on “Cormedix Form 4 insider transactions real-time”? Our system parses every Form 4 the moment it hits EDGAR, translating insider buys, sells, and option grants into plain language trend lines.
Investors typically open Cormedix disclosures to answer three questions: how close is DefenCath to full commercialization, how long will cash last, and are executives buying stock? With Stock Titan, you receive concise “Cormedix earnings report filing analysis,” quick links to the “Cormedix proxy statement executive compensation” tables, and context for each “Cormedix executive stock transactions Form 4.” From quarterly R&D variances to risk-factor shifts tied to catheter lock demand, every filing is captured, summarized, and searchable—so you can focus on decisions, not document hunts.
CorMedix (NASDAQ:CRMD) held its 2025 Annual Meeting of Stockholders on June 24, 2025. Shareholders voted on three key proposals: election of seven directors, advisory vote on executive compensation, and ratification of the independent auditor.
All seven director nominees were successfully elected with Joseph Todisco receiving the highest approval (18.3M votes). The non-binding advisory vote on executive compensation passed with 16.1M votes in favor. Shareholders also approved CBIZ CPAs P.C. as the independent auditor with 45.5M votes in favor.
FAQ
What is the current stock price of Cormedix (CRMD)?
What is the market cap of Cormedix (CRMD)?
What is the main focus of Cormedix Inc?
What type of product is DefenCath?
How does Cormedix generate revenue?
In which market segments does Cormedix operate?
What regulatory standards does the company adhere to?
How is Cormedix positioned within its competitive landscape?
What makes Cormedix's approach to product development unique?
Who are the intended beneficiaries of Cormedix's products?
